Zimmer Biomet Holdings, Inc. reported strong Q4 2025 results, with organic constant currency sales growth of 5.4% and EPS of $2.42, exceeding expectations. The company is undergoing a significant transformation of its U.S. sales force to enhance specialization and productivity, which is expected to cause some short-term disruption but drive long-term mid-single-digit growth. For 2026, Zimmer Biomet forecasts organic constant currency revenue growth of 1% to 3% and adjusted EPS of $8.30 to $8.45, with a continued focus on innovation and leveraging its dedicated sales channel.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Q4 2025 Earnings Call Transcript
Zimmer Biomet Holdings, Inc. reported strong Q4 2025 results, with organic constant currency sales growth of 5.4% and EPS of $2.42, exceeding expectations. The company is undergoing a significant transformation of its U.S. sales force to enhance specialization and productivity, which is expected to cause some short-term disruption but drive long-term mid-single-digit growth. For 2026, Zimmer Biomet forecasts organic constant currency revenue growth of 1% to 3% and adjusted EPS of $8.30 to $8.45, with a continued focus on innovation and leveraging its dedicated sales channel.